RICERCA
AUTORI
RIVISTE
Sfoglia per AUTORE
GARRONE O
Collezione AO Cuneo
Items : 56
Baseline Cytokine Profile Identifies a Favorable Outcome in a Subgroup of Colorectal Cancer Patients Treated with Regorafenib. in Vaccines / Vaccines (Basel). 2023 Feb 2;11(2):335. doi: 10.3390/vaccines11020335.
2023
AO Cuneo
Abbona A; Ricci V; Paccagnella M; Granetto C; Ruatta F; Cauchi C; Galizia D; Ghidini M; Denaro N; Merlano MC; Garrone O;
Why Oncologists Should Feel Directly Involved in Persuading Patients with Head and Neck Cancer to Quit Smoking. in Oncology / Oncology. 2023;101(4):252-256. doi: 10.1159/000528345. Epub 2022 Dec 20.
2023
AO Cuneo
Bossi P; Garrone O; Galizia D; Abbona A; Paccagnella M; Minei S; Merlano MC; Denaro N;
Long-Term Outcomes With Pharmacological Ovarian Suppression During Chemotherapy in Premenopausal Early Breast Cancer Patients. in Journal of the National Cancer Institute / J Natl Cancer Inst. 2022 Mar 8;114(3):400-408. doi: 10.1093/jnci/djab213.
2022
AO Cuneo
Lambertini M; Boni L; Michelotti A; Magnolfi E; Cogoni AA; Mosconi AM; Giordano M; Garrone O; Arpino G; Poggio F; Cinacchi P; Bighin C; Fregatti P; Pronzato P; Blondeaux E; Del Mastro L;
Effect of Eribulin on Angiogenesis and the Expression of Endothelial Adhesion Molecules. in Anticancer research / Anticancer Res. 2022 Jun;42(6):2859-2867. doi: 10.21873/anticanres.15767.
2022
AO Cuneo
Abbona A; Paccagnella M; Astigiano S; Martini S; Denaro N; Ruatta F; Barbieri O; Merlano M; Garrone O;
How Chemotherapy Affects the Tumor Immune Microenvironment: A Narrative Review. in Biomedicines / Biomedicines. 2022 Jul 28;10(8):1822. doi: 10.3390/biomedicines10081822.
2022
AO Cuneo
Garrone O; Ghidini M; Paccagnella M; Abbona A; Minei S; Denaro N; Galizia D; Ruatta F; Occelli M; Merlano MC;
Circulating Cytokines in Metastatic Breast Cancer Patients Select Different Prognostic Groups and Patients Who Might Benefit from Treatment beyond Progression. in Vaccines / Vaccines (Basel). 2022 Jan 5;10(1):78. doi: 10.3390/vaccines10010078.
2022
AO Cuneo
Paccagnella M; Abbona A; Michelotti A; Geuna E; Ruatta F; Landucci E; Denaro N; Vanella P; Lo Nigro C; Galizia D; Merlano M; Garrone O;
In reply to immune desert in head and neck squamous cell carcinoma: A review of challenges and opportunities for modulating the tumor immune microenvironment. in Oral oncology / Oral Oncol. 2022 Jan;124:105640. doi: 10.1016/j.oraloncology.2021.105640. Epub 2021 Nov 26.
2022
AO Cuneo
Denaro N; Merlano M; Garrone O;
Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial. in The Lancet. Oncology / Lancet Oncol. 2022 Dec;23(12):1571-1582. doi: 10.1016/S1470-2045(22)00632-5. Epub 2022 Nov 10.
2022
AO Cuneo
ASL Città di Torino
Lambertini M; Colantuoni G; Puglisi F; Montemurro F; Bighin C; Correale P; Poletti P; Mansutti M; Alicicco MG; Urracci Y; Gasparro S; Garrone O; Fabi A; Cognetti F; Vaccaro A; Nisticò C; Turletti A; Bisagni G; Rimanti A; Gravina A; De Laurentiis M; Forestieri V; Giuliano M; Blondeaux E; De Placido S; Poggio F; Boni L; Del Mastro L;
Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2021 Sep;154:21-29. doi: 10.1016/j.ejca.2021.05.008. Epub 2021 Jul 2.
2021
AO Cuneo
Conte P; De Salvo GL; Magni G; Cinefra M; Vicini R; Genovesi E; Moretti G; Beninato T; Orlando L; Pastina I; Dieci MV; Garrone O; Gori S; Zambelli A; Ferro A; Andreetta C; Amoroso V; De Rossi C; Zamagni C; Frassoldati A; Bengala C; Mariani G; Bisagni G; Cinieri S; Giorgi CA; Guarneri V;
Overall Survival in Metastatic Breast Cancer Patients in the Third Millennium: Results of the COSMO Study. in Clinical breast cancer / Clin Breast Cancer. 2021 Oct;21(5):e489-e496. doi: 10.1016/j.clbc.2020.11.001. Epub 2020 Nov 9.
2021
AO Cuneo
Porcu L; Barni S; Farina G; Berardi R; Moretti A; Frassoldati A; Foglietta J; Zaniboni A; Rimanti A; Bareggi C; Brunello A; Palumbo R; Garrone O; Bonotto M; Pinotti G; Blasi L; Collovà E; La Verde N;
Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial. in The Lancet. Oncology / Lancet Oncol. 2021 Oct;22(10):1458-1467. doi: 10.1016/S1470-2045(21)00352-1. Epub 2021 Sep 17.
2021
AO Cuneo
AOU Città della Salute di Torino
Bruzzi P; Montemurro F; Ballestrero A; Lambertini M; Amaducci L; Campadelli E; Arpino G; Moretti G; Tamberi S; Bighin C; Puglisi F; Barone C; Garrone O; Fabi A; Gori S; De Placido S; Urracci Y; Sanna G; Mura S; Michelotti A; Poggio F; Frassoldati A; Cognetti F; Durando A; Ponzone R; Del Mastro L; Mansutti M; Bisagni G;
Cytokine Profiling of End Stage Cancer Patients Treated with Immunotherapy. in Vaccines / Vaccines (Basel). 2021 Mar 8;9(3):235. doi: 10.3390/vaccines9030235.
2021
AO Cuneo
Basiricò M; Gammaitoni L; Galizia D; Crosetto N; Bertetto O; Merlotti A; Ruatta F; Denaro N; Fea E; Ricci V; Granetto C; Falletta A; Paccagnella M; Abbona A; Merlano MC; Sangiolo D; Aglietta M; Garrone O;
Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer. in NPJ breast cancer / NPJ Breast Cancer. 2021 Jun 28;7(1):82. doi: 10.1038/s41523-021-00286-w.
2021
ASL Città di Torino
AO Cuneo
AOU Città della Salute di Torino
De Placido S; Del Mastro L; Cognetti F; Ardizzoni A; Gravina A; Colantuoni G; Gamucci T; Garrone O; Turletti A; Durando A; Bisagni G; Giuliano M; De Laurentiis M; Bighin C; Puglisi F; Gerratana L; Lambertini M; Ceppi M; Boni L; Montemurro F; Russo S;
The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial. in Scientific reports / Sci Rep. 2021 Jul 2;11(1):13770. doi: 10.1038/s41598-021-92774-z.
2021
AO Cuneo
Vici P; Ciliberto G; Sanguineti G; Di Leo A; De Maria R; Daralioti T; Sperduti I; Perracchio L; di Benedetto A; Del Medico P; Roselli M; Vaccaro A; Garufi C; Cazzaniga M; Lorusso V; Russo A; Pistelli M; Giotta F; Meattini I; Garrone O; Paris I; Sarobba G; Veltri E; Corsi D; D'Ostilio N; Grassadonia A; Valerio MR; Mirabelli R; Fabbri MA; et alii...
Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study. in Breast cancer research and treatment / Breast Cancer Res Treat. 2021 Dec;190(3):415-424. doi: 10.1007/s10549-021-06375-5. Epub 2021 Sep 21.
2021
ASL Asti
AO Cuneo
AOU Città della Salute di Torino
Vallini I; Clivio L; Di Mauro P; Cogliati V; Capici S; Toniolo D; Tralongo P; Turletti A; Valenza R; Valerio MR; Vici P; Spadaro P; Taverniti C; Scognamiglio G; Sarobba MG; Schintu MG; Saracchini S; Santini D; Riccardi F; Putzu C; Nicolini M; Musolino A; Sarti S; Marchetti P; Grassadonia A; Leonardi V; Giovanardi F; Gianni L; Generali D; et alii...
Complete response to immunotherapy in sinonasal undifferentiated carcinoma. in Tumori / Tumori. 2021 Dec;107(6):NP101-NP104. doi: 10.1177/03008916211026971. Epub 2021 Jul 6.
2021
AO Cuneo
Denaro N; Merlano M; Numico G; Garrone O; Bossi P;
Unusual Fatal Outcome Following Administration of a Combination of anti-PD1 and anti-CTLA4 in Metastatic Renal Cell Carcinoma: Liver Toxicity Case Report and a Literature Review. in European journal of case reports in internal medicine / Eur J Case Rep Intern Med. 2021 Jun 17;8(7):002639. doi: 10.12890/2021_002639. eCollection 2021.
2021
AO Cuneo
Denaro N; Garrone O; Occelli M; Fea E; Granetto C; Merlano MC; Numico G;
Final analysis of the PROMISEGIM6 phase III trial assessing GnRH agonist use during chemotherapy as a strategy to preserve ovarian function in premenopausal patients with early breast cancer in Journal of Clinical Oncology
2021
AO Cuneo
Garrone O; Arpino G; Mosconi AM; Lambertini M; Blondeaux E; Del Mastro L; Pronzato P; Bighin C; Fregatti P; Poggio F; Cinacchi P; Giordano M; Cogoni AA; Magnolfi E; Michelotti A; Boni L;
Effect of moderate physical exercise on the immune system modulation in patients with breast cancer during preoperative chemotherapy: The NEO-RUNNER study in Journal of Clinical Oncology
2021
AO Cuneo
Ruatta F; Denaro N; Merlano MC; Prina AV; Rubini D; Vanella P; Paccagnella M; Croce N; Falletta A; Abbona A; Garrone O; Vandone AM;
Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2020 Sep;136:43-51. doi: 10.1016/j.ejca.2020.05.007. Epub 2020 Jul 4.
2020
AO Cuneo
Ceppi M; Boccardo F; Miglietta L; Cardinali B; Fregatti P; Montemurro F; Puglisi F; Garrone O; Gamucci T; De Placido S; Nisticò C; Cognetti F; Valle E; De Laurentiis M; Blondeaux E; Bighin C; Poggio F; Lambertini M; Bruzzone M; Conte B; Del Mastro L;
Exploratory analysis of circulating cytokines in patients with metastatic breast cancer treated with eribulin: the TRANSERI-GONO (Gruppo Oncologico del Nord Ovest) study. in ESMO open / ESMO Open. 2020 Oct;5(5):e000876. doi: 10.1136/esmoopen-2020-000876.
2020
AO Cuneo
Crosetto N; Falletta A; Lo Nigro C; De Angelis C; Vanella P; Geuna E; Abbona A; Vandone AM; Montemurro F; Michelotti A; Paccagnella M; Garrone O; Di Maio M; Merlano M;
Treating patients with cancer amidst the COVID-19 pandemic: experience of a regional hospital in the Piedmont region in northern Italy. in Tumori / Tumori. 2020 Oct;106(5):427-431. doi: 10.1177/0300891620942313. Epub 2020 Jul 23.
2020
AO Cuneo
Crosetto N; Colantonio I; Di Costanzo G; Fea E; Ricci V; Cauchi C; Occelli M; Vandone AM; Granetto C; Vanella P; Ruatta F; Denaro N; Garrone O; Merlano MC;
PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2(+) Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype. in Clinical cancer research : an official journal of the American Association for Cancer Research / Clin Cancer Res. 2020 Nov 15;26(22):5843-5851. doi: 10.1158/1078-0432.CCR-20-1731. Epub 2020 Aug 25.
2020
AO Cuneo
Prat A; D'Amico R; Paré L; Chic N; Urso L; Griguolo G; Curtarello M; Orvieto E; Piacentini F; Nanni O; Cagossi K; Bertone E; Garrone O; Rimanti A; Giotta F; Musolino A; Cavanna L; Frassoldati A; Brandes AA; Bisagni G; Dieci MV; Guarneri V; Conte P;
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence. in Journal of cellular physiology / J Cell Physiol. 2020 Nov;235(11):7900-7910. doi: 10.1002/jcp.29445. Epub 2020 Jan 15.
2020
AO Cuneo
Vici P; Giordano A; Barba M; Mazzotta M; Sperduti I; Ciliberto G; Villa A; Risi E; De Maria R; Del Medico P; Generali D; Meattini I; Livi L; Garrone O; Baldini E; Zamagni C; Pistelli M; Cannita K; Valerio MR; Berardi R; Russo A; Ricciardi G; Adamo V; Ficorella C; Roselli M; Lorusso V; Landucci E; Paris I; Giotta F; et alii...
Immune escape mechanisms in head and neck squamous cell carcinoma and implication for new immunotherapy approach. in Current opinion in oncology / Curr Opin Oncol. 2020 May;32(3):203-209. doi: 10.1097/CCO.0000000000000623.
2020
AO Cuneo
Merlano MC; Denaro N; Garrone O;
Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial. in International journal of cancer / Int J Cancer. 2020 Jul 1;147(1):160-169. doi: 10.1002/ijc.32789. Epub 2019 Dec 4.
2020
ASL Città di Torino
AO Cuneo
AOU Città della Salute di Torino
Del Mastro L; Ceppi M; Montemurro F; Puglisi F; Garrone O; Fabi A; Bisagni G; Durando A; Turletti A; Urracci Y; Cognetti F; De Laurentiis M; Giuliano M; Bighin C; de Azambuja E; Conte B; Poggio F; Bruzzone M; Lambertini M;
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies. in Breast care (Basel, Switzerland) / Breast Care (Basel). 2020 Feb;15(1):30-37. doi: 10.1159/000495469. Epub 2019 Apr 17.
2020
AO Cuneo
Mustacchi G; Pronzato P; Torri V; Marchetti P; Montemurro F; Riccardi F; Romagnoli E; Bisagni G; Livi L; Natoli C; Donadio M; Biganzoli L; Del Mastro L; Clivio L; Giordano M; Frassoldati A; Scavelli C; Ferzi A; Schirone A; Palumbo R; Gebbia V; Fabi A; Santini D; Turletti A; Porpiglia M; Atzori F; Blasi L; De Laurentiis M; Artale S; et alii...
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study. in Journal of experimental & clinical cancer research : CR / J Exp Clin Cancer Res. 2020 Dec 10;39(1):279. doi: 10.1186/s13046-020-01797-3.
2020
AO Cuneo
Roselli M; Del Medico P; Cazzaniga M; Garufi C; Sarobba G; Giotta F; Paris I; Garrone O; Veltri E; Corsi D; D'Ostilio N; Fabbri MA; Russo A; Mirabelli R; Valerio MR; Marchetti P; Tomao S; Marinelli D; Mazzotta M; Barchiesi G; Zamagni C; Tonini G; Adamo V; Michelotti A; Moscetti L; Bria E; Cassano A; La Verde N; Generali D; et alii...
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting. in International journal of cancer / Int J Cancer. 2020 Apr 1;146(7):1917-1929. doi: 10.1002/ijc.32583. Epub 2019 Aug 7.
2020
AO Cuneo
Vici P; Di Leo A; Barba M; Villa A; Ciliberto G; Sperduti I; De Maria R; Risi E; Generali D; De Tursi M; Sarobba G; Del Medico P; Meattini I; Desideri I; Livi L; Baldini E; Di Cocco B; Foglietta J; Greco F; Zamagni C; Garrone O; D'Ostilio N; Sini V; Cannita K; Adamo V; Ricciardi GRR; Fiorio E; Pistelli M; Russo A; et alii...
Expression and subcellular localization of the bromodomain-containing protein 7 is a prognostic biomarker in breast cancer. in Anti-cancer drugs / Anticancer Drugs. 2020 Apr;31(4):423-430. doi: 10.1097/CAD.0000000000000897.
2020
AO Cuneo
Garrone O; Vivenza D; Brizio R; Mantovani F; Del Sal G; Merlano M; Crook T; Lo Nigro C;
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial. in BMC medicine / BMC Med. 2019 Nov 21;17(1):207. doi: 10.1186/s12916-019-1445-z.
2019
AOU Città della Salute di Torino
AO Cuneo
Guarneri V; Conte PF; Griguolo G; D'Amico R; Vicini R; Balduzzi S; Amaducci L; Moretti G; Foschini MP; Bazan V; Gambaro AR; Romito S; Sarti S; Cagossi K; Ferro A; Danese S; Piacentini F; Soto Parra H; Zamagni C; Beano A; Rimanti A; Donadio M; Garrone O; Musolino A; Gebbia V; Aieta M; Cavanna L; Giotta F; Frassoldati A; et alii...
Trastuzumab-related cardiotoxicity in patients with nonlimiting cardiac comorbidity. in The breast journal / Breast J. 2019 May;25(3):444-449. doi: 10.1111/tbj.13240. Epub 2019 Apr 1.
2019
ASL Torino 5
ASL Asti
AO Cuneo
AOU Città della Salute di Torino
ASL Vercelli
Bonzano A; Milani A; D'Alonzo A; Bellini E; Pizzuti L; Barone C; Del Mastro L; Garrone O; Airoldi M; Vici P; Becco P; Martinello R; Montemurro F;
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2019 Mar 1;30(3):418-423. doi: 10.1093/annonc/mdz007.
2019
AO Cuneo
Miglietta F; Orvieto E; Sanders M; Maiorana A; Piacentini F; Ferro A; Sarti S; Cagossi K; Bertone E; Garrone O; Rimanti A; Giotta F; Cavanna L; Musolino A; Frassoldati A; Brandes AA; Bisagni G; Conte P; Dieci MV; Balduzzi S; D'Amico R; Guarneri V;
Knowing the tumour microenvironment to optimise immunotherapy. in Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale / Acta Otorhinolaryngol Ital. 2019 Feb;39(1):2-8. doi: 10.14639/0392-100X-2481.
2019
AO Cuneo
Merlano MC; Abbona A; Denaro N; Garrone O;
Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study. in Breast (Edinburgh, Scotland) / Breast. 2019 Dec;48:7-16. doi: 10.1016/j.breast.2019.07.006. Epub 2019 Aug 22.
2019
ASL Asti
AO Cuneo
AOU Città della Salute di Torino
ASL Città di Torino
ASL Vercelli
Clivio L; Cavanna L; Ciccarese M; Vici P; Valerio MR; Valenza R; Turletti A; Tralongo P; Toniolo D; Taverniti C; Spadaro P; Scognamiglio G; Schintu MG; Sarobba MG; Saracchini S; Santini D; Riccardi F; Nicolini M; Putzu C; Musolino A; Melegari E; Marchetti P; Leonardi V; Grassadonia A; Giovanardi F; Generali D; Gianni L; Gebbia V; Gambaro AR; et alii...
The HERBA Study: A Retrospective Multi-Institutional Italian Study on Patients With Brain Metastases From HER2-Positive Breast Cancer. in Clinical breast cancer / Clin Breast Cancer. 2019 Aug;19(4):e501-e510. doi: 10.1016/j.clbc.2019.05.006. Epub 2019 May 18.
2019
AO Cuneo
Valerio M; Marchetti F; Russo A; Barni S; Galanti D; Leonardi V; Cavanna L; Foglietta J; Turazza M; Cretella E; Laudadio L; Vici P; Garrone O; Tarenzi E; Frassoldati A; La Verde N; Fabi A; Moroso S; Gori S; Puglisi F; Lunardi G; Alongi F; Inno A;
How I treat squamous ENT cancer. in ESMO open / ESMO Open. 2019 Jul 16;4(Suppl 2):e000542. doi: 10.1136/esmoopen-2019-000542. eCollection 2019.
2019
AO Cuneo
Merlano MC; Denaro N; Galizia D; Garrone O;
Activation of immune response in refractory patients to standard treatment in Journal of Translational Medicine
2019
AO Cuneo
Occelli M; Abbona A; Sangiolo D; Nigro CL; Garrone O; Falletta A; Anna M; Varamo C; Aglietta M; Gammaitoni L; Monteverde M; Merlano M;
Correction: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ? 65 years: new lessons for clinical practice from the EVA study. in Oncotarget / Oncotarget. 2018 Oct 2;9(77):34639-34640. doi: 10.18632/oncotarget.26213. eCollection 2018 Oct 2.
2018
ASL Città di Torino
AO Cuneo
Clivio L; Torri On Behalf Of The Eva Study Group V; Frassoldati A; Scavelli C; Palumbo R; Ferzi A; Schirone A; Cursano MC; Fabi A; Gebbia V; Benedetto C; Atzori F; Turletti A; Blasi L; Piezzo M; Artale S; Mentuccia L; La Verde N; Bianchi G; Musolino A; Vici P; Maur M; Pistelli M; Garrone O; Generali D; Zambelli A; Febbraro A; Arcangeli V; Diodati L; et alii...
Correction 2: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ? 65 years: new lessons for clinical practice from the EVA study. in Oncotarget / Oncotarget. 2018 Nov 30;9(94):36720-36721. doi: 10.18632/oncotarget.26431. eCollection 2018 Nov 30.
2018
ASL Città di Torino
AO Cuneo
Torri V; Frassoldati A; Clivio L; Scavelli C; Ferzi A; Palumbo R; Gebbia V; Schirone A; Fabi A; Benedetto C; Cursano MC; Turletti A; Atzori F; Artale S; Blasi L; Piezzo M; Bianchi G; Maur M; La Verde N; Mentuccia L; Vici P; Musolino A; Pistelli M; Garrone O; Generali D; Zambelli A; Febbraro A; Arcangeli V; Diodati L; et alii...
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2018 Dec 1;29(12):2328-2333. doi: 10.1093/annonc/mdy414.
2018
AOU Città della Salute di Torino
AO Cuneo
Guarneri V; Balduzzi S; D'Amico R; Amaducci L; Bajardi EA; Vicini R; Beano A; Schirone A; Moretti G; Lombardo L; Giovanardi F; Cagossi K; Russo A; Pronzato P; Rimanti A; Danese S; Zamagni C; Maltoni R; Ferro A; Molino A; Musolino A; Aieta M; Gebbia V; Giotta F; Cavanna L; Piacentini F; Garrone O; Brandes AA; Donadio M; et alii...
Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ? 65 years: new lessons for clinical practice from the EVA study. in Oncotarget / Oncotarget. 2018 Aug 7;9(61):31877-31887. doi: 10.18632/oncotarget.25874. eCollection 2018 Aug 7.
2018
ASL Città di Torino
AO Cuneo
Torri On Behalf Of The Eva Study Group V; Clivio L; Scavelli C; Frassoldati A; Ferzi A; Palumbo R; Gebbia V; Schirone A; Fabi A; Cursano MC; Turletti A; Benedetto C; Atzori F; Piezzo M; Artale S; Blasi L; La Verde N; Bianchi G; Maur M; Mentuccia L; Vici P; Musolino A; Garrone O; Pistelli M; Zambelli A; Febbraro A; Generali D; Diodati L; Arcangeli V; et alii...
Incidence of cetuximab-related infusion reaction in head and neck cancer patients: may we predict it? in ESMO open / ESMO Open. 2018 Jun 20;3(4):e000404. doi: 10.1136/esmoopen-2018-000404. eCollection 2018.
2018
AO Cuneo
Merlano MC; Garrone O;
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study. in Breast (Edinburgh, Scotland) / Breast. 2017 Oct;35:115-121. doi: 10.1016/j.breast.2017.06.043. Epub 2017 Jul 13.
2017
AO Cuneo
ASL Città di Torino
Clivio L; Zambelli A; Blasi L; Torri V; Sartori D; Scavelli C; Schirone A; Turletti A; Vici P; Valerio MR; Palumbo R; Pistelli M; Musolino A; Porpiglia M; Arcangeli V; Artale S; Atzori F; Ballerio A; Bianchi GV; Moretti G; Maur M; Michelotti A; La Verde N; Generali D; Gebbia V; Garrone O; Fumagalli A; Frassoldati A; Ficorella C; et alii...
Eribulin in advanced breast cancer: safety, efficacy and new perspectives. in Future oncology (London, England) / Future Oncol. 2017 Dec;13(30):2759-2769. doi: 10.2217/fon-2017-0283. Epub 2017 Sep 13.
2017
AO Cuneo
Merlano MC; Lingua D; Vandone AM; Vanella P; Miraglio E; Garrone O;
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience. in Oncotarget / Oncotarget. 2017 May 25;8(34):56921-56931. doi: 10.18632/oncotarget.18176. eCollection 2017 Aug 22.
2017
AO Cuneo
Ciliberto G; Di Cocco B; Marolla P; Sanguineti G; Garrone O; Della Giulia M; Laudadio L; Greco F; Barni S; Lorusso V; Cannita K; Russo A; Adamo V; Giotta F; Tomao S; Ficorella C; Alberti AM; Landucci E; Rossi E; Barba M; Maugeri-Saccà M; Sini V; Mauri M; D'Onofrio L; Scinto AF; Zampa G; Bertolini I; Botticelli A; Piacentini F; et alii...
Heterogeneity of colon cancer: from bench to bedside. in ESMO open / ESMO Open. 2017 Aug 22;2(3):e000218. doi: 10.1136/esmoopen-2017-000218. eCollection 2017.
2017
AO Cuneo
Garrone O; Ricci V; Fea E; Merlano MC; Granetto C;
5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial. in Breast cancer research and treatment / Breast Cancer Res Treat. 2016 Jan;155(1):117-26. doi: 10.1007/s10549-015-3655-1. Epub 2015 Dec 10.
2016
AO Cuneo
ASL Cuneo 2
Conte P; Bruzzi P; Castiglione F; Landucci E; Pastorino S; Pronzato P; Bighin C; Miglietta L; Accortanzo V; Durando A; Danese S; Garrone O; Piras M; Scotto T; Michelotti A; Cavazzini G; Adami F; Levaggi A; Del Mastro L;
Eribulin in pretreated metastatic breast cancer patients: results of the TROTTER trial-a multicenter retrospective study of eribulin in real life. in SpringerPlus / Springerplus. 2016 Jan 21;5:59. doi: 10.1186/s40064-016-1700-0. eCollection 2016.
2016
ASL Torino 4
ASL Asti
AO Cuneo
AOU Città della Salute di Torino
ASL Biella
ASL Vercelli
ASL Alessandria
AOU Novara
Merlano MC; Polimeni MA; Oletti MV; Lucio F; Airoldi M; De Conciliis E; La Verde N; Vandone AM; Donadio M; Giacobino A; Saggia C; Montemurro F; Garrone O;
Immune-related response criteria: light and shadows. in ESMO open / ESMO Open. 2016 Jul 7;1(4):e000082. doi: 10.1136/esmoopen-2016-000082. eCollection 2016.
2016
AO Cuneo
Garrone O; Occelli M; Merlano M;
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2?×?2 factorial, randomised phase 3 trial. in Lancet (London, England) / Lancet. 2015 May 9;385(9980):1863-72. doi: 10.1016/S0140-6736(14)62048-1. Epub 2015 Mar 2.
2015
AO Cuneo
Cognetti F; Forestieri V; Bisagni G; Bighin C; Papaldo P; Gravina A; Gamucci T; Giuliano M; Colantuoni G; Ardizzoni A; Barni S; Montemurro F; Puglisi F; Garrone O; Valle E; Durando A; Nisticò C; Turletti A; Cavazzini G; Boni C; De Placido S; De Laurentiis M; Bruzzi P; Del Mastro L;
Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival: A Randomized Clinical Trial. in JAMA / JAMA. 2015 Dec 22-29;314(24):2632-40. doi: 10.1001/jama.2015.17291.
2015
AO Cuneo
Boni L; Del Mastro L; Sertoli MR; Pronzato P; Vecchio C; Bighin C; Poggio F; Giraudi S; Giordano M; Gamucci T; Scotto T; Levaggi A; Garrone O; Gori S; Michelotti A; Lambertini M;
The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer. in PloS one / PLoS One. 2015 Sep 4;10(9):e0136731. doi: 10.1371/journal.pone.0136731. eCollection 2015.
2015
ASL Cuneo 1
AO Cuneo
AOU Novara
Mentuccia L; Laudadio L; Zoboli A; Marchetti F; Bogina G; Lunardi G; Boni L; Gamucci T; Evangelisti L; Barni S; Saracchini S; Amaducci L; Santini D; Fabi A; Garrone O; Frassoldati A; Cavanna L; Saggia C; Bria E; Cretella E; Vici P; Spazzapan S; Iezzi L; De Simone V; Duranti S; Cavazzini MG; Turazza M; Gubiotti M; Foglietta J; et alii...
Expression profiling and long lasting responses to chemotherapy in metastatic gastric cancer. in International journal of oncology / Int J Oncol. 2010 Nov;37(5):1219-28. doi: 10.3892/ijo_00000773.
2010
AO Cuneo
Merlano M; Comino A; Borghi F; Ceppi M; Gallo F; Heouaine A; Monteverde M; Riba M; Lattanzio L; Tonissi F; Garrone O; Lo Nigro C;
Single-agent pegylated liposomal doxorubicin (Caelix) in chemotherapy pretreated non-small cell lung cancer patients: a pilot trial. in Lung cancer (Amsterdam, Netherlands) / Lung Cancer. 2002 Jan;35(1):59-64. doi: 10.1016/s0169-5002(01)00269-0.
2002
AO Cuneo
Gasco M; Ciura PL; Garrone O; Mariani G; Costanzo GD; Granetto C; Castiglione F; Numico G; Ostellino O; Porcile G; Merlano M;
[The treatment of laryngeal cancer. Chemotherapeutic treatment]. in Recenti progressi in medicina / Recenti Prog Med. 1998 Dec;89(12):647-50.
1998
AO Cuneo
Merlano M; Garrone O;